Für den Inhalt der Angaben zeichnet die Projektleitung verantwortlich.
Dieses von der Gebert Rüf Stiftung geförderte Projekt wird von folgenden weiteren Projektpartnern mitgetragen: Swiss Federal Institute of Technology (EPFL); Centre Hospitalier Universitaire Vaudois (CHUV); Lausanne University (UNIL)
Förderbeitrag: CHF 321'273
Dauer: 01.2018 - 06.2019
Handlungsfeld: Pilotprojekte, 1998 - 2018
Ecole Polytechnique Fédérale de Lausanne
Laboratory of Microsystems 4
STI IMT LMIS4, Station 17
1015 Lausanne (Schweiz)
- david.bonzon@epfl. ch
Single cell isolation is essential to unlock novel phenotypic and genotypic personalized diagnoses and treatments. Yet, the lack of appropriate single cell isolation methods still hinders the dissemination of the approach. The ideal technology must isolate single cells with efficiency while avoiding doublet cells (aggregates). It must be disposable, sterile, and easy to use. Cell viability and functionality must be preserved. Most importantly, it must provide an indisputable proof of single-cell isolation to comply with regulatory requirements for an immediate process validation. None of the existing methods fulfill all of these criteria, above all the immediate proof of clonality.
To address this need, our team will develop an innovative tool and method that meets all of the essential criteria for single cell isolation. Our technology employs impedance spectroscopy to allow for the traceable isolation of single cells. In order to transfer the technology to the industry, scientific and technological development is required to complete the phase of proof of concept. This will lead to the design and creation of a novel approach for efficient isolation of single cells based on our core impedance-based technology.
Upon completion, the team will incorporate a startup company and develop a prototype to convince key opinion leaders of the value proposition. The ambition is to bring to the market a novel pipetting system to enable biotech companies and researchers to isolate single-cell lines reliably and cost-effectively by reducing lab time and validation time. Such enabling technology will fasten the development of novel biotherapeutics and, in the long run, it will open the door to personalized medicine.
Was ist das Besondere an diesem Projekt?
The project is highly innovative because it was designed conjointly with key opinion leaders in the field of regenerative medicine. We invented a new generation of pipetting systems that makes use of the latest development in impedance-based sensors and microfluidics. According to the statement "small is beautiful", our technologies will revolutionize the way researchers will isolate single cells. In the future, our game-changing pipetting systems will also benefit other applications, including cell-based assays (drug screening); single-cell omics (cancer diagnosis); and inline monitoring (biotherapeutics).
The project is currently entering the proof-of-concept phase. A demonstrator was built and pre-validated in the course of the PhD theses of the two project leaders. The product concept has been validated with potential customers in the field of personalized medicine. Contacts were made with key opinion leaders who expressed their willing to test the prototype, once available.
No publication to date.
No publication to date.
Am Projekt beteiligte Personen
Letzte Aktualisierung dieser Projektdarstellung 17.10.2018